LEXINGTON, MASSACHUSETTS, USA, September 26, 2008 – RainDance Technologies announced today the launch of the dScreen Consortium, a research initiative conducted with sanofi-aventis, Paris (EURONEXT: SAN and NYSE: SNY), and Louis Pasteur University of Strasbourg, France, to develop the
LEXINGTON, MASS. – Sept. 26, 2008 — RainDance Technologies, Inc., a provider of innovative droplet-based microfluidic solutions for human health and disease research, today dedicated its new headquarters and operations building and unveiled its new RDT 1000 instrument. Keynoting the e
RainDance Technologies® is making complex genetics simple. The company’s ultra-sensitive genomic tools enable research of novel non-invasive liquid biopsy applications that should result in more accurate, reliable, cost-effective, and early detection of cancer and other inherited and infectious diseases. Major research institutions and laboratories around the world rely on the performance of RainDance systems. Based outside Boston, Massachusetts, the company supports customers using RainDrop® Digital PCR, as well as the ThunderStorm® and ThunderBolts™ Next-Generation Sequencing Enrichment Systems through its international sales and service operations, as well as a global network of distributors and commercial service providers. Both technology platforms have been recognized by The Scientist as Top 10 Innovations with the RainDrop System winning the award in 2014 and the ThunderStorm System winning the award in 2011.